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INTRODUCTION
Inflammation is a dynamic response of vascularized tissues
to injury and an important part of the body’s defense mech-
anisms (1). Although inflammation is importantly required
for homeostasis, excessive inflammation may induce various
diseases including cancer (2-5). Cigarette smoking has been
known to induce cancer in a variety of tissues including lung
through chronic inflammation (6). Previous studies have sho-
wn that cigarette smoking induces proteins related in inflam-
mation, so called inflammation markers (7, 8). Tumor necro-
sis factor alpha (TNF- ) and white blood cells (WBCs) are
well known inflammatory markers. Cytokines such as TNF-
are important inducers of inflammatory response, and the
existing evidence implicates the role of TNF- in inflamma-
tory pathways that increase a variety of diseases (9-13). In one
large prospective study (Honolulu Heart Program), persons
with WBC count in highest tertile had 30% increased risk
of dying from cancer compared with persons in the lowest
tertile (14). Another prospective study has shown that eleva-
tion in WBC count within the clinically normal range is asso-
ciated with increased risk of several chronic diseases related
to inflammation (15). Therefore, it is believed that increased
TNF- level and WBC count play important roles in smok-
ing-induced inflammation which could be associated with
increased risk of diseases (16).
Glutathione S-transferase (GST) M1 and P1 are detoxifi-
cation enzymes, which have a pivotal role in catalyzing the
conjugation of glutathione (GSH) to electrophilic substrates
(17, 18). Because of this function of GSTM1 and GSTP1,
they may protect against inflammation and oxidative stress
through detoxification of various toxic substances in tobac-
co smoke (19, 20). Several studies have demonstrated that
individuals lacking the GSTM1 activity have increased risk
of smoking-related diseases (21, 22). Moreover, the GSTP1
protein was reported to be very important in metabolism of
many carcinogenic compounds including benzo[a]pyrene
diolepoxide (BPDE) which is one of the most important car-
cinogenic metabolites in tobacco smoke (20). 
The human GSTM1 is polymorphic and its deletion is res-
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GSTM1 and GSTP1 Polymorphisms as Potential Factors for Modifying
the Effect of Smoking on Inflammatory Response
Inflammation has been known to be an important underlying condition for develop-
ment of various diseases including cancer. The aims of this study were to investi-
gate whether tobacco smoke exposure increases the level of inflammation biomar-
kers and the GSTM1 and GSTP1 gene polymorphisms are associated with inflam-
matory response due to tobacco smoke exposure. We measured urinary cotinine
level in 300 healthy university students. Total serum TNF- levels and blood WBC
counts were determined to evaluate inflammatory response. Allelic loss of the GSTM1
and the GSTP1 (Ile105Val) polymorphism were determined by PCR and RFLP.
Tobacco smoke exposure was found to be associated with increase of both TNF-
level and WBC count. Particularly, smokers with combination of GSTM1 null and
GSTP1 AG or GG genotypes showed higher TNF- level than those with the other
genotype combinations (p=0.07). This result suggests that smoking may induce
inflammation measured as TNF- level or WBC count and combinations of the
GSTM1 and GSTP1 polymorphisms may modify the effect of smoking on serum
TNF- level.
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ponsible for the existence of a null type lacking the enzyme
function (23). Furthermore, a polymorphic site at codon 105
(A to G substitution replacing isoleucine with valine) of GS-
TP1 is known to change the kinetic property of the enzyme
in binding with a few of electrophilic substrates including
PAH diolepoxides (24). For this reason, GSTM1 and GSTP1
gene polymorphisms may contribute to susceptibility to in-
flammation-related diseases. These results also suggest that
GSTM1 and GSTP1 gene polymorphisms may be involved
in the detoxification of toxic substances in cigarette smoke
to change the levels of TNF- and WBC, which are inflam-
matory markers. Therefore, in the present study we tried to
investigate whether tobacco smoke exposure increases the
level of inflammation biomarkers and the GSTM1 and GSTP1
gene polymorphisms are associated with inflammatory res-
ponse due to tobacco smoke exposure. 
MATERIALS AND METHODS
Study population and sampling
A total of 300 students at Inha University, Incheon, Korea,
were recruited during September 2002 after exclusion of
students having conditions affecting inflammatory biomark-
ers such as inflammatory disorder or medication of anti-infl-
ammatory drugs. Information on demographic characteristics
and lifestyle habits including smoking and alcohol consump-
tion were collected by trained interviewers using a structured
questionnaire. We controlled fasting state by asking them
for overnight fasting to participate in this study and sam-
plings of blood and urine were done in the morning. After
collecting venous blood samples from subjects, whole blood
in a heparinized tube was kept at 4℃ for counting of blood
WBC and serum in a plain tube was separated by centrifuga-
tion within 4 hr and frozen at -70℃for the analysis of TNF-
level. In addition, urine was kept frozen at -20℃for the ana-
lysis of cotinine level. The study protocol was approved by
the institutional review board at Inha University Hospital
and written informed consent was provided by all study sub-
jects.
Measurement of serum TNF- levels and blood WBC
counts 
Serum TNF- level was determined by enzyme-linked
immunosorbent assay (ELISA) according to the manufac-
turer’s instructions (R&D Systems, Minneapolis, MN, U.S.A.).
The detection limit of the assay was 0.12 pg/mL. In addition,
the count of blood WBC was measured using cell counter. 
Measurement of urinary cotinine levels 
Urinary cotinine levels were determined for monitoring
tobacco exposure. After urine samples were centrifuged to
remove particulate matter, cotinine level was analyzed by a
liquid phase radioimmunoassay method using the fundamen-
tal principles of a competitive reaction between antibodies
and 125I-labeled cotinine and urinary cotinine (DPC, Los Ange-
les, CA, U.S.A.). After allowing antigen-antibody reaction for
30 min, the fraction bound to antibody was precipitated and
its radioactivity was measured for 1 min using Cobra D5010
Quantum, a gamma-counter (Packard, Meriden, CT, U.S.A.).
Urinary cotinine level was adjusted to urine creatinine.
Genotyping assays
Genomic DNA was extracted from peripheral blood lym-
phocytes using a QIAamp DNA Blood Mini Kit (Qiagen,
Valencia, CA, U.S.A.), and analyzed using PCR and RFLP
method for GSTM1 and GSTP1 gene polymorphisms. The
20  L PCR reaction mixture used for GSTM1 and GSTP1
genotyping contained 10 mM of Tris-HCl (pH 9.0), 40 mM
of KCl, 1.5 mM of MgCl2, 0.25 mM of each dNTP, 1 unit
of Taq polymerase (Bioneer, Seoul, Korea), 20 pmole of the
forward and reverse primers, and 50 ng of genomic DNA as
a template. Amplifications were performed using the follow-
ing conditions; initial denaturation at 94℃ for 5 min, 35
cycles with denaturation at 94℃ for 1 min, annealing at 65
℃for 1 min, and extension at 72℃for 1 min, and then com-
pletion at 72℃ for 7 min. PCR amplification of reaction
mixtures was carried out using a thermal cycler, PTC-200
(MJ Research, Watertown, MA, U.S.A.).
GSTM1 and GSTP1 genotypes were determined using a
multiplex PCR method. Primer sets for GSTM1 and GSTP1
genes were used for the amplification reaction. The primers
designed were: GSTM1-forward, 5′ -GAACTCCCTGAAA-
AGCTAAAGC-3′ , GSTM1-reverse, 5′ -GTTGGGCTCAA-
ATATACGGTGG-3′ ; GSTP1-forward, 5′ -CCAGTGACT-
GTGTGTTGATC-3′ , GSTP1-reverse, 5′ -CAACCCTGG-
TGCAGATGCTC-3′ . The PCR products were digested with
restriction enzyme BsmA I at 55℃ for 3 hr for GSTP1 geno-
typing and detected by electrophoresis on 3% 3:1 NuSieve/
agarose gel (Cambrex Bio Science, Rockland, ME, U.S.A.).
Genotyping of the GSTM1 gene was determined based on
the presence of a 215-bp product. For the genotyping of the
GSTP1 gene, the 189-bp PCR product remained intact for
the A allele, but was cleaved into smaller fragments of 149-
bp and 40-bp in the case of the G allele. For confirming the
analyses, ten percent of the samples were randomly chosen
and genotyped again, producing identical results. 
Statistical analysis
Means and the distributions of characteristic variables acco-
rding to smoking status were compared using the t-test or
chi-square test. The t-test was used to analyze relationships
between TNF- level or WBC count and subject character-Genetic Effect on Inflammatory Response Related to Smoking 1023
istics such as age, sex, body mass index (BMI), smoking sta-
tus, cotinine level, and the GSTM1 and GSTP1 genotypes.
The effects of smoking on total serum TNF- level and blood
WBC count were evaluated by linear regression analysis. Cor-
relation between smoking amounts obtained from question-
naire and urinary cotinine level was evaluated by Spearman’s
and Kendall’s rank correlations as well as Pearson’s correla-
tion analysis. Analysis of variance (ANOVA) was used to eval-
uate the effects of genotype combinations on inflammatory
markers according to smoking amount or cotinine level. For
smokers, pack year value was calculated to indicate cumula-
tive cigarette dose (pack years=[cigarettes/day÷20]×years
of smoking). A probability level of 0.05 was used as the cri-
terion of statistical significance based on two-sided test. SAS,
version 8.1 (SAS institute Inc., Cary, NC, U.S.A.) was used
for the statistical analysis. 
RESULTS
The demographic characteristics of the study subjects by
smoking status are listed in Table 1. Mean pack year of smok-
ers was 3.56 (range, 0.15-9.00). BMI and the GSTM1 geno-
type showed no significant differences with respect to smok-
ing status. However, urinary cotinine level, age, sex, alcohol
consumption, and the GSTP1 genotype were found to be
significantly different in distribution according to smoking
status (cotinine, p<0.01; age, p<0.01; sex, p<0.01; alcohol
consumption, p<0.01; and GSTP1, p=0.02, respectively). 
Total serum TNF- levels and blood WBC counts accord-
ing to age, sex, BMI, alcohol consumption, and GSTM1 and
GSTP1 genotypes are listed in Table 2. Age, sex, and alcohol
consumption were not found to be significantly related to
TNF- level or WBC count. Obesity was found to be signifi-
cantly associated with increase of WBC count (p<0.01), but
the observed increase of TNF- with obesity did not reach
*p-value from chi-square test for categorical variables or t-test for continuous variables analysis.
Smoking status
Nonsmoker (n=170) Smoker (n=130) p-value*
Variables
Cumulative cigarette dose (mean [range, pack year]) 3.56 (0.15-9.00)
Urinary cotinine level (mean±SD [ g/g creatinine]) 38.63±170.55 1456.60±1651.40 <0.01
Age (mean±SD [yr]) 23.8±1.6 24.6±1.4 <0.01
Sex (% male) 88.2 99.2 <0.01
Body mass index (mean±SD [kg/m
2]) 22.58±2.59 23.01±2.70 0.16
Alcohol consumption (% drinker) 80.6 94.6 <0.01
GSTM1 genotype (% present) 44.1 50.0 0.31
GSTP1 genotype (% AA) 67.7 54.6 0.02
Table 1. Demographic characteristics of the study population according to smoking status
TNF- (pg/mL)
Number (%)
Mean (SE) p-value*
Variables
WBC (×10
9 cell/L)
Mean (SE) p-value*
Age (yr)
<25  172 (57.3) 2.97 (0.28) 6.02 (0.13)
≥25 128 (42.7) 2.95 (0.26) 0.96 6.08 (0.14) 0.79
Sex
Male 279 (93.0) 2.95 (0.20) 6.06 (0.10)
Female 21 (7.0) 3.13 (0.65) 0.82 5.88 (0.33) 0.62
Body mass index
�(kg/m
2)
<22.5 150 (50.0) 2.62 (0.18) 5.70 (0.12)
≥22.5 150 (50.0) 3.30 (0.34) 0.08 6.35 (0.14) <0.01
Alcohol consumption
No 40 (13.3) 2.73 (0.30) 6.07 (0.21)
Yes 260 (86.7) 3.00 (0.22) 0.47 6.04 (0.11) 0.93
GSTM1 genotype
Present 140 (46.7) 2.55 (0.12) 6.07 (0.16)
Null 160 (53.3) 3.32 (0.35) 0.04 6.02 (0.12) 0.82
GSTP1 genotype
AA  186 (96.3) 2.80 (0.16) 5.89 (0.12)
AG or GG 114 (38.0) 3.22 (0.44) 0.38 6.30 (0.17) 0.04
Table 2. Total serum TNF- levels and blood WBC counts according to subject characteristics and genotypes
*p-value from t-test, 
� BMI dichotomized by median value.1024 J.-H. Kim, S.-G. Park, K.-H. Lee, et al.
statistical significance (p=0.08). Subjects with the GSTM1
null genotype had significantly higher TNF- level than those
with the GSTM1 present genotype (p=0.04). However, the
GSTM1 genotype did not affect WBC count (p=0.82). Sub-
jects with the GSTP1 AG or GG genotype had significantly
higher WBC count than those with GSTP1 AA genotype
(p=0.04). TNF- level was also higher in subjects with the
GSTP1 AG or GG genotype than those with the GSTP1 AA
genotype, although this difference did not reach statistical
significance (p=0.38). 
Cotinine level has been used to differentiate active smokers
from nonsmokers because cotinine is widely considered to
be the best marker for monitoring tobacco exposure in either
actively or passively exposed individuals. However, as shown
in Table 3, the information of smoking amount obtained from
questionnaire showed better relationships with inflammatory
biomarkers (TNF- , p=0.18; and WBC, p<0.01, respective-
ly) than urinary cotinine level (TNF- , p=0.37; and WBC,
p=0.04, respectively) after adjustment of age, sex, and BMI,
although smoking amount and cotinine level showed good
correlation (Pearson, correlation coefficient=0.56, p<0.01; Spe-
arman, correlation coefficient=0.83, p<0.01; and Kendall, cor-
relation coefficient=0.70, p<0.01, respectively).
The effects of smoking on serum TNF- level and blood
WBC count were evaluated after stratification according to
the GSTM1 or GSTP1 gene polymorphism to estimate whe-
ther the GSTM1 and GSTP1 gene polymorphisms modify the
relation between smoking and serum TNF- level or blood
WBC count. In the linear regression analysis after adjustment
of age, sex, and BMI, none of the GSTM1 and GSTP1 geno-
types showed statistically significant effect on the relation
between serum TNF- level or blood WBC count and smok-
ing exposure measured by smoking amount or urinary coti-
nine level (all of four strata, p>0.1). Since the metabolism of
the toxins from tobacco smoke is extremely complex, single
gene may not have enough impact on inflammation. In an
attempt to address this complexity, we constructed and analy-
zed composite genotypes (Fig. 1, 2). Combination of GSTM1
null and GSTP1 AG or GG genotypes in subjects with pack
year or cotinine level over zero showed higher TNF- level
than the other genotype combinations, although the differ-
ences were not statistically significant (ANOVA, pack year,
p=0.07; and cotinine, p=0.15, respectively) (Fig. 1). This trend
was also shown in linear regression (pack year, ptrend=0.07; and
cotinine, ptrend=0.15, respectively). However, combination of
GSTM1 null and GSTP1 AG or GG genotypes in subjects
with pack year or cotinine level over zero did not show higher
WBC count than the other genotype combinations, although
subjects with pack year or cotinine level over zero showed
increased WBC count than those with pack year or cotinine
level zero in all genotype combinations (ANOVA, pack year,
p=0.34; and cotinine, p=0.15, respectively) (Fig. 2).
TNF- (pg/mL)
Mean* ptrend
� Variables Number (%)
*Mean and 
� p-trend were obtained by linear regression after controlling
for age, sex, and BMI.
WBC (×10
9 cell/L)
Mean* ptrend
�
Smoking amount (pack year)
0 170  (59.0) 2.81 0.18 5.97 <0.01
<4 71 (24.7) 3.62 6.03
≥4 47 (16.3) 3.59 6.96
Cotinine ( g/g creatinine)
0 143  (47.7) 2.86 0.37 5.98 0.04
<600 65 (21.7) 3.47 6.03
≥600 92 (30.7) 3.41 6.54
Table 3. Effects of smoking amount or cotinine level on serum
TNF- level or blood WBC count
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Fig. 1. Serum TNF- levels according to combinations of GSTM1 and GSTP1 polymorphisms in strata divided by pack year (A) or urinary
cotinine level (B). M1, GSTM1 present; M1*, GSTM1 null; P1: GSTP1 AA; P1*, GSTP1 AG or GG. ANOVA was used to compare the means
of TNF- levels according to genotype combinations in strata divided by pack year (pack year=0, p=0.40; and pack year >0, p=0.07, res-
pectively) or cotinine level (cotinine=0, p=0.41; and cotinine >0, p=0.15, respectively). The number in each bar indicates number of subjects
included in strata of each genotype combination in smoker and nonsmoker.
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TNF- protein has been known to play an important role
in a variety of diseases through inflammatory reaction and
tobacco smoke has been known to induce inflammation-relat-
ed diseases including cancer (6-11). Therefore, inflammation-
related diseases caused by smoking may be promoted through
increase of TNF- level. However, the effect of smoking on
TNF- level was inconsistent in previous reports. Kuschner
and coworkers reported that smokers had higher level of pul-
monary TNF- than nonsmokers (6), but Keatings and co-
workers did not show the elevated TNF- level in asympto-
matic smokers (25). Our data also did not support the signifi-
cant association between smoking amount and TNF- level.
However, when we analyzed the effect of smoking on TNF-
level according to genotype combination, smoking showed
marginally significant effect on TNF- level in subjects with
combination of GSTM1 null and GSTP1 AG or GG geno-
types in spite of low level of tobacco smoke exposure. More-
over, WBCs were significantly increased by smoking regard-
less of genotypes. These results indicate that smoking can
increase the levels of inflammation biomarkers, particularly
in subjects with combination of GSTM1 null and GSTP1
AG or GG genotypes. The relationship between smoking
and inflammation-induced carcinogenesis is biologically plau-
sible. Oxidative stress such as the formation of reactive oxy-
gen species (ROS) is a key component of inflammation, and
they lead to damage of macromolecules such as DNA, pro-
tein, and lipid, eventually cancer when ROS are generated
in large amounts (19, 20, 26). Moreover, GST enzymes have
been reported to protect against endogenous or exogenous
oxidative damage (27, 28). These facts support that GST en-
zymes may protect against inflammation through oxidative
damage induced by toxic chemicals contained in tobacco smo-
ke. Although host antioxidant defences such as GSTs detox-
ify ROS, individuals differ in their ability to deal with oxi-
dant burden, and such differences are, in part, genetically
determined (29). Inability to detoxify ROS due to genetic
variation is likely to perpetuate the inflammatory process
which could be associated with a variety of diseases. 
We hypothesized that elevated TNF- is a good indicator
of inflammation caused by smoking and serum TNF- level
would be associated with GST polymorphisms in relation to
smoking. The present study showed that subjects with the
combination of GSTM1 null and GSTP1 AG or GG geno-
types have higher TNF- level than those with the other
genotype combinations. This result suggests that there are
interactions between GSTM1 and GSTP1 genetic polymor-
phisms, thus subjects with the combination of GSTM1 null
and GSTP1 AG or GG genotypes are more susceptible to
smoking-induced inflammation than those with the other
genotype combinations. The previous study by Ryberg and
coworkers support the interaction between GSTM1 and GS-
TP1 genetic polymorphisms (30). In their study, when the
effects of combined GSTM1 and GSTP1 genotypes on DNA
adduct formation were examined, lung cancer patients with
GSTM1 null and GSTP1 AG or GG genotype combinations
had significantly higher carcinogen-derived DNA adduct
level in lung tissue than those with the other genotype com-
binations. This genotype combination effect was not found
in WBC count in our study. The reason may be that the ele-
vation of WBC count may be relatively late and consequen-
tial event rather than causal event in inflammatory pathway
while TNF- is considered as a proinflammatory cytokine
and a causal factor of inflammation because the binding of
TNF- to its receptors results in the activation of major tran-
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Fig. 2. Blood WBC counts according to combinations of GSTM1 and GSTP1 polymorphisms in strata divided by pack year (A) or urinary
cotinine level (B). M1, GSTM1 present; M1*, GSTM1 null; P1: GSTP1 AA; P1*, GSTP1 AG or GG. ANOVA was used to compare the means
of WBC counts according to genotype combinations in strata divided by pack year (pack year=0, p=0.77; and pack year >0, p=0.34,
respectively) or cotinine level (cotinine=0, p=0.95; and cotinine >0, p=0.15, respectively). The number in each bar indicates number of
subjects included in strata of each genotype combination in smoker and nonsmoker.
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50scription factors such as AP-1 and NFkB which in turn in-
duce genes involved in acute and chronic inflammatory res-
ponses (9). Moreover, TNF- may be induced through exces-
sive oxidative stress by toxic chemicals contained in tobacco
smoke although the level may be modified by GSTM1 and
GSTP1 enzymes. For this reason, TNF- may be more rele-
vant as a biomarker indicating inflammation which could be
associated with a variety of diseases than WBC count, although
both TNF- and WBC are indicators of inflammation. 
In our study, questionnaire information of smoking showed
better relationship with TNF- level or WBC count than
urinary cotinine level, although cotinine is widely considered
to be the best marker for monitoring tobacco exposure. Study
subjects sometimes intend to stop smoking before study and
half life of cotinine in the body is very short (about 17 hr).
Therefore, change of smoking habit before study may lead
to the change of urinary cotinine level, which may undermine
relationship between urinary cotinine level and TNF- level
or WBC count. In addition, our study showed borderline sig-
nificance of smoking on TNF- level, probably due to small
sample size. Therefore, this study results should be confirmed
through studies of larger subjects. In conclusion, our study
findings suggest that smoking may induce inflammation
measured as TNF- level or WBC count and combinations
of the GSTM1 and GSTP1 polymorphisms may modify the
effect of smoking on serum TNF- level, indicating genetic
susceptibility to smoking-related diseases.
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